Hence, we hypothesized that GRP-R could serve as a novel immunotherapeutic target and we sought to evaluate whether GRP-R mAbs could efficaciously inhibit tumorigenesis and metastasis, as well as eliminate residual tumors in high-risk neuroblastoma using in vitro and in vivo neuroblastoma tumor models. This evidence concerns the gene GRPR and neuroblastoma.